Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events. However, as the evidence in favour of variou...

Descripción completa

Detalles Bibliográficos
Autores principales: Schernthaner, Guntram, Shehadeh, Naim, Ametov, Alexander S., Bazarova, Anna V., Ebrahimi, Fahim, Fasching, Peter, Janež, Andrej, Kempler, Péter, Konrāde, Ilze, Lalić, Nebojša M., Mankovsky, Boris, Martinka, Emil, Rahelić, Dario, Serafinceanu, Cristian, Škrha, Jan, Tankova, Tsvetalina, Visockienė, Žydrūnė
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585305/
https://www.ncbi.nlm.nih.gov/pubmed/33097060
http://dx.doi.org/10.1186/s12933-020-01154-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585305/
https://www.ncbi.nlm.nih.gov/pubmed/33097060
http://dx.doi.org/10.1186/s12933-020-01154-w

Ejemplares similares